After BCR and Bcl-2 inhibitors became available and their efficacy in high-risk CLL patients was shown [259,260,261], considerations on the risk–benefit effects of an allo-HSCT in CLL have led to a dramatic decrease in the number of allo-HSCTs performed in both Europe and the United States [262,263,264]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.